HHS Secretary Kennedy Restructures Vaccine Panel
U.S. Health and Human Services Secretary Robert F. Kennedy Jr. recently took significant steps to alter a key government vaccine panel. He believes this change was necessary to remove what he described as “persistent conflicts of interest.” His announcement followed a press conference alongside Centers for Medicare and Medicaid Services Administrator Mehmet Oz.
However, new findings from the USC Schaeffer Center for Health Policy & Economics seem to contradict Kennedy’s claims. Researchers noted that conflicts within the Centers for Disease Control and Prevention panel had been at “historic lows” prior to Kennedy’s changes. In fact, many of the new members he appointed have been recognized as skeptics of vaccines.
The research, published in the journal JAMA, revealed that the most troubling form of conflict, namely income from vaccine manufacturers, had nearly disappeared among the Advisory Committee on Immunization Practices (ACIP) members. Additionally, low rates of conflicts were reported on another advisory panel, the Vaccines and Related Biological Products Advisory Committee (VRBPAC), which also holds considerable sway in determining U.S. vaccine policy.
Kennedy has long insisted that the advisors on these panels maintain close connections to the pharmaceutical industry, even claiming during his Senate confirmation hearing that 97% of the CDC panel members faced conflicts of interest. Yet, lead study author Genevieve Kanter found this assessment excessive after examining the vaccine data herself.
“I thought that number sounded alarming at first,” Kanter stated. “But after looking into it, I didn’t see anything supporting such a high figure.” She also expressed that the research might reassure the public and the Trump administration regarding issues previously considered critical.
The study’s timeframe covered reported financial conflicts between 2000 and 2024 among experts in both vaccine panels. Those panels meet multiple times each year to evaluate vaccines. Members must disclose any ties to vaccine manufacturers or their competitors before discussing specific products. While some panelists can participate with waivers for essential expertise, those with significant conflicts are recused.
From 2016 onwards, an average of 6.2% of ACIP members and 1.9% of VRBPAC members reported financial conflicts at any given meeting. Notably, fewer than 1% of these conflicts stemmed from personal income received from vaccine makers.
By 2024, reported conflicts among ACIP members dropped to 5%, while VRBPAC members maintained a rate below 4%. In stark contrast, conflicts were much higher in the early 2000s, reaching around 43% for ACIP in 2000 and 27% for VRBPAC in 2007. This decline may be tied to stricter policies imposed on the FDA panel in 2007 and a rising awareness of conflicts in decision-making.
The study observed that the most common conflict involved research support, which is typically regarded as less troubling than income-related ties. Kanter noted that having experts in research is essential for evaluating vaccine safety and efficacy.
“Many of the conflicts are related to expertise rather than personal gain,” she explained. “That’s the type of insight we want on these committees.” While there might be a perception that ACIP members report conflicts at a higher rate than VRBPAC members, Kanter mentioned that the data from the CDC is less detailed.
Overall, while conflicts of interest should be scrutinized in healthcare regulation, Kanter indicated that other areas might present more significant concerns than the vaccine panels.
Latest in Health Care
In other news, Warren Buffett’s Berkshire Hathaway has recently invested in UnitedHealth, lifting its stock price above $300, bouncing back from a low of under $235 this month. The investment figures suggest Buffett’s confidence in the company’s recovery, although analysts express caution about underlying structural problems taking over a year to resolve.
Health Care Technology Updates
At Epic’s annual Users Group Meeting in Verona, Wisconsin, AI developments were a hot topic. The company confirmed it is working on an AI-powered clinical documentation tool, which aims to streamline note-taking for clinicians. This move underscores the growing interest in AI solutions to alleviate staff burnout and reduce administrative burdens.
During the event, Epic’s founder, Judy Faulkner, highlighted the company’s commitment to combining human intelligence with AI capabilities, indicating that many features are still in the pipeline but hold great promise for the future.
